Patrick Chaltin

Cytura Therapeutics BV is a Dutch company that focuses on finding a solution to stop destabilization of the genome. The company is based in Oss, Netherlands. The company aims to target genomic instability as a stand-alone therapy or in combination therapy to avoid therapy resistance or relapse, which will help make cancer treatment more effective and improve the lives of patients worldwide. The company was founded by Ad W. van Gorp, who has been the CEO since incorporation.

Cytura Therapeutics BV is a Dutch company that focuses on finding a solution to stop destabilization of the genome. The company is based in Oss, Netherlands. The company aims to target genomic instability as a stand-alone therapy or in combination therapy to avoid therapy resistance or relapse, which will help make cancer treatment more effective and improve the lives of patients worldwide. The company was founded by Ad W. van Gorp, who has been the CEO since incorporation.

Cytura Therapeutics BV is a Dutch company that focuses on finding a solution to stop destabilization of the genome. The company is based in Oss, Netherlands. The company aims to target genomic instability as a stand-alone therapy or in combination therapy to avoid therapy resistance or relapse, which will help make cancer treatment more effective and improve the lives of patients worldwide. The company was founded by Ad W. van Gorp, who has been the CEO since incorporation.